Sulfonylureas, dipeptidyl peptidase-4 inhibitors (DPP-4i) and SGLT2 inhibitors (SGLT2i) lacked evidence of reduced stroke risk in RCT [5]. This evidence concerns the gene SLC5A2 and Stroke.